SUBSCRIBE
SUBSCRIBE
News   Policy

FDA Denies Somaxon Pharmaceuticals, Inc. Approval for Insomnia Drug

February 27, 2009 | 
1 min read
Feb 26 (Reuters) - Somaxon Pharmaceuticals Inc said the U.S. health regulators denied approval for its experimental treatment for insomnia in the present form and raised several issues regarding the efficacy data of the drug.
Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS).
Vaccines
FDA’s Prasad Links 10 Child Deaths to COVID-19 Vaccines, Eyes Stricter Review Guidelines
December 1, 2025
 · 
2 min read
 · 
Tristan Manalac
Office worker, employee being late for work, looking untidy. Deadlines and time management. Contemporary art collage. Concept of business, office lifestyle, career, challenges
FDA
FDA Delays Decision on Ascendis’ Dwarfism Drug by Three Months
December 1, 2025
 · 
1 min read
 · 
Tristan Manalac
A scientist with pill bottles in front of FDA headquarters
Regulatory
FDA Action Alert: BMS, GSK, Amgen and More
December 1, 2025
 · 
5 min read
 · 
Tristan Manalac
Concept World kidney day, handcraft paper blue kidneys and stethoscope on yellow background. Copy space. Banner.
Approvals
Otsuka Secures IgAN Win as FDA Approves First Anti-APRIL Antibody
November 26, 2025
 · 
2 min read
 · 
Tristan Manalac